




Validation Data



Flow cytometry: 1×10^6 Cynomolgus PBMC (treated with 50 ng/mL PMA and 1 μ g/mL Ionomycin for 4-6 hours in the presence of monensin) were surface-stained with ABflo® 450 Rabbit anti-Human/Monkey CD3 mAb (A27177, 5 μ l/Test) and then intracellularly-stained with PE/Cyanine7 Rabbit IgG isotype control (5 μ l/Test, left) or PE/Cyanine7 Rabbit anti-Human/Monkey IFN-gamma mAb (A27517, 5 μ l/Test, right). Cells in the lymphocyte gate were used for analysis.

Flow cytometry: 1×10^6 Human PBMC (untreated, left) and Human PBMC (treated with 50 ng/mL PMA and 1 μ g/mL Ionomycin for 4-6 hours in the presence of monensin, right) were intracellularly-stained with PE/Cyanine7 Rabbit anti-Human IFN-gamma mAb (A27517, 5 μ l/Test, orange line) or PE/Cyanine7 Rabbit IgG isotype control (5 μ l/Test, blue line). Non-fluorescently stained cells were used as blank control (red line).

Flow cytometry: 1×10^6 Human PBMC (untreated, left) and Human PBMC (treated with 50 ng/mL PMA and 1 μ g/mL Ionomycin for 4-6 hours in the presence of monensin, right) were intracellularly-stained with PE/Cyanine7 Rabbit anti-Human IFN-gamma mAb (A27517, 5 μ l/Test).